Management of Extramedullary Leukemia as a Presentation of Acute Myeloid Leukemia
|
|
- Stuart Carroll
- 5 years ago
- Views:
Transcription
1 Original Article 1165 of Extramedullary Leukemia as a Presentation of Acute Myeloid Leukemia Samuel J. Slomowitz, MD, and Paul J. Shami, MD Abstract Extramedullary involvement is considered to be an uncommon presentation of acute myeloid leukemia (AML), although some data suggest it may be present in up to 30% of patients. Extramedullary involvement by AML can present in a variety of clinical manifestations, most notably in the form of myeloid sarcoma, leukemia cutis, and central nervous system involvement. Each presents a unique clinical scenario in terms of symptoms and management. Extramedullary disease in any form presenting without evidence of bone marrow disease is still considered evidence of systemic disease and is usually treated as such. Most commonly, extramedullary disease presents concurrently with bone marrow disease, and although it may require additional local therapy in the form of intrathecal chemotherapy or radiation, the principles of systemic treatment remain unchanged. The prognostic impact of extramedullary disease is unclear. Specifically, whether hematopoietic stem cell transplantation should be considered in first remission irrespective of other prognostic factors has not been established. Patients who undergo transplantation have similar outcomes as patients without extramedullary disease, although they do have a higher rate of extramedullary relapse. More research is needed to define the molecular basis for extramedullary disease, its prognostic impact, and optimal management. (JNCCN 2012;10: ) Extramedullary presentation of acute myeloid leukemia (AML) is considered uncommon, although in one series it occurs in up to 30% of patients. 1 Extramedullary involvement usually reflects systemic disease. Very rarely extramedullary disease presents without evidence of overt hematologic disease and if untreated, virtually all of these patients will develop systemic disease. 2 Extramedullary AML can present in a variety of forms. These include myeloid sarcoma (also termed granulocytic sarcoma, chloroma, or myeloblastoma), leukemia cutis (LC), and central nervous system (CNS) disease. Extramedullary disease at presentation or relapse can pose unique clinical problems. In general, the basic principles of systemic therapy remain the same. The prognostic impact of extramedullary disease is the object of some controversy. Some series suggest a negative effect on prognosis while others do not. 1,3,4 Additionally, extramedullary disease has been correlated with specific AML phenotypes and chromosomal abnormalities. This article discusses the 3 main forms of extramedullary AML, namely CNS disease, LC, and myeloid sarcoma. CNS Leukemia From the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah. Submitted April 7, 2012; accepted for publication July 8, Dr. Slomowitz had disclosed that he has no financial interests, arrangements, or affilations with the manufacturers of any products discussed in this article or their competitors. Dr. Shami has disclosed that he receives clinical research support from Eisai Inc., Cyclacel Pharmaceuticals, Inc., and Genzyme Corporation; he is on the speakers bureau for Novartis; and is the Chief Scientific Officer, Chairman of the Board of Directions, and owns stock in JSK Therapeutics, Inc. Correspondence: Paul J. Shami, MD, Huntsman Cancer Institute, Suite 2100, 2000 Circle of Hope, Salt Lake City, UT paul.shami@utah.edu AML presenting with CNS involvement is rare, particularly when compared with acute lymphoblastic leukemia. Older published data had suggested that in relapsed AML, rates of CNS disease were as high as 10% to 11%. 5,6 More recent studies estimate the actual occurrence to be less than 5%, and probably in the 2% to 3% range of cases at presentation or relapse. 1,7 The actual incidence at presentation is not well defined for a variety of reasons. Because CNS involvement is a relatively rare event, lumbar punctures are not routinely performed at diagnosis in the absence of neurologic
2 1166 Slomowitz and Shami symptoms. This practice also stems from the concern that performing a lumbar puncture with circulating blasts may lead to seeding of the CNS space during a traumatic procedure. Furthermore, with the modern AML treatment programs that include high doses of cytarabine, patients actually receive CNS treatment, rendering relapse in that space less common. Similar to other forms of extramedullary involvement, a relationship exists between CNS involvement and myelomonocytic and monoblastic phenotypes (French-American-British [FAB] subtypes M4 and M5). 1 A recent review of patients at MD Anderson Cancer Center found that in confirmed cases of CNS disease at presentation or relapse, certain cytogenetic abnormalities occur at a higher frequency than other types of AML. 7 Specifically, inv(16), chromosome 11 abnormalities, and complex cytogenetics were more frequently associated with CNS disease. Although a WBC count of 100,000/mcL is generally considered a risk factor for CNS involvement, 8 the mean WBC count associated with CNS involvement in that study was around 36,500/mcL. 7 The limited data on CNS involvement by AML at presentation makes it hard to determine whether this occurrence constitutes an independent risk factor. Data from pediatric AML series show that in that age group, CNS disease is not associated with a worse survival in general, although these patients do have a higher risk of isolated CNS relapse. 9 On the other hand, the MD Anderson series suggests that CNS disease is associated with worse outcomes. 7 However, in that study, patients with relapsed disease were also included, thus raising the possibility that the inherent negative prognostic impact of relapse may have confounded the analysis. A lumbar puncture at diagnosis to evaluate the cerebrospinal fluid (CSF) is not routine practice. However, if a patient presents with symptoms suggestive of CNS disease, a lumbar puncture may be warranted. Before the procedure, brain imaging is recommended to ensure that no mass effect nor intracranial hemorrhage is present, particularly in the setting of thrombocytopenia. It is also prudent to reduce the WBC count to a relatively safe level (with hydroxyurea, for instance) to decrease the risk of CNS contamination in case of a traumatic lumbar puncture. Analysis of the CSF should include cytology and flow cytometry. In the rare occurrence of relapsed acute promyelocytic leukemia, CNS evaluation may be warranted at relapse once the coagulopathy has resolved, even in the absence of CNS symptoms. Although routine CSF sampling at presentation is not performed in all patients, a few high-risk presentations may warrant a lumbar puncture in first remission, including myelomonocytic and monoblastic phenotypes, a WBC count at presentation greater than 100,000/mcL, or a lymphoblastic component in the setting of biphenotypic leukemias. 8 Lactate dehydrogenase has been shown to be statistically higher in patients with AML who have CNS involvement, and may be helpful in selecting patients for a lumbar puncture. 6,7 Treatment for CSF disease involves direct intrathecal chemotherapy and systemic chemotherapy with good CNS penetration. For intrathecal chemotherapy, agents generally used are methotrexate and/or cytarabine. Although no standard intrathecal protocol has been established, one approach consists of treating patients twice weekly until clearance of CSF cytology, followed by weekly treatments for 4 to 6 weeks. No single agent is considered superior, and most patients will obtain rapid clearance of their CSF. Additionally, high-dose cytarabine given during either induction or consolidation achieves adequate CNS levels and may obviate the need for additional intrathecal treatments. 8 In patients who present with a CNS chloroma, cranial irradiation should be considered. However, patients should not receive cranial radiation, high-dose cytarabine, or intrathecal chemotherapy concurrently because of the increased risk of neurotoxicity. Leukemia Cutis LC represents infiltration of the skin by leukemic cells. It is a relatively rare but well-known clinical finding in AML, and published data estimate its occurrence at 3% of cases. 1,10 Similar to CNS infiltration, it is more frequent in myelomonocytic and monoblastic phenotypes. It is also important to recognize that not all skin lesions at presentation are LC. A variety of skin reactions can occur in response to infections, medications, and inflammation that may have a similar appearance. Consequently, a skin biopsy is essential
3 1167 of Extramedullary AML to confirm LC. The only cytogenetic aberrations that have been shown in a prospective series, as opposed to case reports, to be associated with LC are abnormalities of chromosome LC can occur at presentation, after diagnosis, or at relapse, but is very rare in the absence of systemic involvement. Appearance of LC without evidence of systemic disease almost always heralds later development of systemic bone marrow disease. 11 LC is often manifested as a violaceous papular rash. In infants it has been described as having a blueberry muffin appearance. Historically, concern was expressed that LC may be a manifestation of more aggressive leukemias. In a large prospective analysis of 381 patients with AML, patients with LC did not differ from those without LC in terms of remission rates. However, a nonstatistically significant trend was seen toward shorter remission when LC was present. 10 An analysis of 202 patients who underwent allogeneic transplant for AML at Memorial Sloan-Kettering Cancer Center showed that the overall risk of relapse posttransplant was not higher in patients who had LC than in those who did not. 12 However, patients with LC had a significantly higher rate of extramedullary relapse. 12 Despite the lack of definitive data to that effect, LC is often considered an indication of more aggressive disease and therefore an indicator of poor prognosis. 13 Similar to other extramedullary manifestations of leukemia, the presence of LC is considered to be evidence of systemic disease and is treated with standard systemic chemotherapy. Presentation without marrow involvement is exceedingly rare and a negative bone marrow study is presumed to represent a sampling error or bone marrow involvement below the level of detection. Because of limited data, the prognostic significance of LC is not totally defined. The suggestion of shorter remission in patients with LC has led some investigators to recommend that hematopoietic stem cell transplantation (HSCT) be considered in these patients. 10 However, other factors involved in the decision to consider HSCT (eg, performance status, age, cytogenetic and molecular markers) must be taken into account. 13 Even without large series to support that point, radiation therapy in patients who obtain a systemic remission but have persistence of LC is a logical treatment. Patients who are in marrow remission with diffuse LC could benefit from total skin electron beam radiation therapy. 14 Lesions can respond rapidly to radiation therapy. Focal radiation can also be used for palliation. 14 To avoid excessive toxicity, caution should be exercised to avoid overlap between intensive chemotherapy and radiation. Myeloid Sarcoma With the exception of LC, myeloid sarcoma is used to describe all extramedullary tissue infiltration with leukemic cells outside the CNS. The incidence of myeloid sarcoma is generally estimated at 2% to 9% in most series. 13 Others have estimated it to be higher. 1 This discrepancy in terms of incidence is explained partly by whether gum hyperplasia is considered myeloid sarcoma without histologic evidence or whether only biopsy-proven cases are included in the separate analyses. Gum hyperplasia alone likely represents the most common physical examination finding suggesting extramedullary disease, and in clinical practice rarely prompts tissue sampling. Soft tissue, periosteum, bone, and lymph nodes are other common sites of involvement. 15 Myeloid sarcoma most often presents at or after diagnosis, and can be the presentation of disease relapse. 16 As with the other forms of extramedullary AML, it is rare in the absence of systemic leukemia, and most patients will develop detectable systemic disease in the absence of treatment. Myeloid sarcoma has rarely been described in association with other myeloid neoplasms, including myelodysplastic syndrome, myeloproliferative disorders, and chronic myeloid leukemia. 2,15,17 A histologic review of 92 cases showed that, similar to other forms of extramedullary AML, FAB M4 and M5 were the most common subtypes of AML associated with myeloid sarcoma (43.5% had monoblastic or myelomonocytic morphology). 17 Higher initial WBC count at presentation is also associated with higher prevalence of myeloid sarcoma involvement. 1 Slightly more data are available in this population regarding the association between specific cytogenetic and molecular abnormalities and incidence of myeloid sarcoma. Abnormalities that have been associated with myeloid sarcoma include t(8;21),
4 1168 Slomowitz and Shami inv(16), 11q23, NPM1, and FLT3 internal tandem duplication mutations. 13,17 However, in prospective series, t(8:21) and 11q23/MLL abnormalities have been associated with myeloid sarcoma with a higher incidence. 1,18 The specific molecular mechanisms that lead to tissue localization have not been totally elucidated. For instance, the neural cell adhesion molecule CD56 has been shown to be expressed in a significant number of myeloid sarcoma specimens. 1,19 However, its role in the pathophysiology of myeloid sarcoma remains to be fully proven. Some reports suggest that extramedullary AML is associated with a poorer overall prognosis. 1,3 However, whether presentations with aleukemic myeloid sarcoma truly have a poorer prognosis is still unclear. For instance, Byrd et al 3 suggested that extramedullary disease impacts negatively on the relatively better prognosis associated with the t(8;21). However, in a limited series reported from the MD Anderson Cancer Center, patients with aleukemic myeloid sarcoma who were treated with AML-type therapy fared better than patients with leukemic AML matched for age and cytogenetics. 4 Certain cytogenetic aberrations are associated with myeloid sarcoma. Whether, in general, presentation with myeloid sarcoma affects the prognostic impact of these individual abnormalities is unclear. MLL gene mutations, specifically the classic 11q23 abnormality [excluding the t(9;11)], has a poor overall prognosis when found in AML. MLL gene mutation has been linked to extramedullary involvement, and prognosis remains poor. 1 Again, the data are limited as to whether the extramedullary involvement itself worsens prognosis in this already high-risk group. As for LC, myeloid sarcoma is often considered an indication of more aggressive disease and consequently a worse prognosis. 13 Myeloid sarcoma most often occurs with concurrent bone marrow involvement, and therefore is usually evidence of systemic disease. Appropriate imaging to identify all potential sites of disease and plan therapy may be warranted. Because myeloid sarcoma generally is associated with systemic disease, the authors believe that, depending on the patient s age and performance status, initial treatment should be based on standard treatment regimens for induction chemotherapy, with very few exceptions. However, data and trials specific to patients with myeloid sarcoma are limited, and no specific chemotherapy program has been shown to be superior for these patients. Whether the presence of myeloid sarcoma worsens prognosis has not been clearly shown, although some evidence suggests this. This raises the question of whether patients with myeloid sarcoma should be considered for HSCT in first remission irrespective of other prognostic factors. A retrospective review of European Group for Blood and Marrow Transplantation (EBMT) data analyzed a cohort of 99 patients with myeloid sarcoma who underwent allogeneic stem cell transplant; 30 patients had isolated myeloid sarcoma. Of the cohort, 52% underwent transplant in first remission. Patients had 5-year leukemia-free and overall survivals of 36% and 48%, respectively, suggesting that this treatment option should be considered in appropriate patients. 20 However, no data show that patients with AML who fall into a more favorable prognostic group should undergo HSCT only because of the presence of extramedullary disease. Consequently, the decision to offer HSCT in first remission to these patients should be individualized based on careful consideration of risks and benefits. The role of radiation therapy in the treatment of myeloid sarcoma is similar to its use in the treatment of LC. It can be considered in an upfront setting if rapid improvement in symptoms is needed, particularly if a vital organ function or structure is compromised or threatened. In general, the lesions are sensitive to relatively low doses of radiation, on the order of 24 Gy in 12 fractions. 21 These doses are not expected to preclude the use of total body irradiation if HSCT is considered. 13 Radiation therapy should also be considered in patients whose extramedullary disease responded to systemic therapy but whose myeloid sarcoma did not show an adequate clinical response, because local recurrence could potentially reseed the bone marrow. 13,21 In the EBMT cohort of patients with myeloid sarcoma, 15% had more than 2 sites of extramedullary involvement. 20 Because of the prevalence of multifocal disease, it is reasonable to consider imaging to identify all sites of extramedullary disease before treatment planning. Cases of isolated myeloid sarcoma with no evidence of systemic involvement pose a unique clinical challenge. It is expected that patients who have iso-
5 1169 of Extramedullary AML lated myeloid sarcoma will eventually have systemic disease. 2 Consequently, these patients are generally approached in a similar fashion to those with overt bone marrow disease at presentation. Radiotherapy should also be considered after chemotherapy for patients with isolated myeloid sarcoma, or if complete resolution of the myeloid sarcoma is not obtained with chemotherapy. 13,21 Finally, myeloid sarcoma as a presentation of relapse is generally considered to be evidence of systemic relapse and should be treated as such. Conclusions Extramedullary disease represents a unique presentation of AML. In general, the treatment principles remain similar to those in situations with overt marrow disease at presentation, with additional therapy targeted at the local site of extramedullary disease. For LC, myeloid sarcoma, and CNS disease, patients should be treated as if systemic disease is present, even if bone marrow studies are negative. Extramedullary disease presenting without systemic disease is rare and most patients will eventually develop systemic disease. The independent prognostic impact of extramedullary AML has not been completely established, but is considered by many as an indication of more aggressive disease. For this reason, in the appropriate patient with LC or myeloid sarcoma, considering HSCT in first remission is justifiable. Intrathecal chemotherapy should be part of the treatment approach for patients with CNS disease. Upfront radiation therapy is an option for all types of extramedullary disease if rapid resolution of symptoms is required or a vital structure is threatened. Isolated recurrence of CNS disease, LC, or myeloid sarcoma should be considered a systemic relapse and treated as such. A clear need exists for further investigation to understand the molecular basis for extramedullary AML and, consequently, its prognostic impact and optimal management. References 1. Chang H, Brandwein J, Yi QL, et al. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res 2004;28: Byrd JC, Edenfield J, Shields DJ, Dawson NA. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995;13: Byrd JC, Weiss RB, Arthur DC, et al. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B J Clin Oncol 1997;15: Tsimberidou AM, Kantarjian HM, Wen S, et al. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 2008;113: Dekker AW, Elderson A, Punt K, Sixma JJ. Meningeal involvement in patients with acute nonlymphocytic leukemia. Incidence, management and predictive factors. Cancer 1985;56: Stewart DJ, Keating MJ, McCredie KB, et al. Natural history of central nervous system acute leukemia in adults. Cancer 1981;47: Shihadeh F, Reed V, Faderl S, et al. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer 2012;118: O Donnell MR, Abboud CN, Altman J, et al. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 1, Available at: NCCN.org. Accessed July 19, Johnston DL, Alonzo TA, Gerbing RB, et al. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a children s oncology group study. Pediatr Blood Cancer 2010;55: Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol 2002;81: Su WP. Clinical, histopathologic, and immunohistochemical correlations in leukemia cutis. Semin Dermatol 1994;13: Michel G, Boulad F, Small TN, et al. Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis. Bone Marrow Transplant 1997;20: Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood 2011;118: Bakst R, Yahalom J. Radiation therapy for leukemia cutis. Practical Radiat Oncol 2011;1: Neiman RS, Barcos M, Berard C, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer 1981;48: Koc Y, Miller KB, Schenkein DP, et al. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999;85: Pileri SA, Ascani S, Cox MC, et al. Myeloid sarcoma: clinicopathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 2007;21: Tallman MS, Hakimian D, Shaw JM, et al. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993;11: Chang CC, Eshoa C, Kampalath B, et al. Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry: correlation with blast differentiation in bone marrow. Am J Clin Pathol 2000;114: Chevallier P, Labopin M, Cornelissen J, et al. Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Hematologica 2011;96: Bakst R, Wolden S, Yahalom J. Radiation therapy for chloroma (granulocytic sarcoma). Int J Radiation Oncology Biol Phys 2012;82:
Acute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationResearch Article Myeloid Sarcoma: Clinicopathologic, Cytogenetic, and Outcome Analysis of 21 Adult Patients
SAGE-Hindawi Access to Research Leukemia Research and Treatment Volume 2011, Article ID 523168, 4 pages doi:10.4061/2011/523168 Research Article Myeloid Sarcoma: Clinicopathologic, Cytogenetic, and Outcome
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationMolecular Markers in Acute Leukemia. Dr Muhd Zanapiah Zakaria Hospital Ampang
Molecular Markers in Acute Leukemia Dr Muhd Zanapiah Zakaria Hospital Ampang Molecular Markers Useful at diagnosis Classify groups and prognosis Development of more specific therapies Application of risk-adjusted
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia
More informationAcute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities
Acute Myeloid Leukemia with Recurrent Cytogenetic Abnormalities Acute Myeloid Leukemia with recurrent cytogenetic Abnormalities -t(8;21)(q22;q22)(aml/eto) -inv(16) or t(16;16) -t(15;17) -11q23 Acute Myeloid
More information1 Introduction. 1.1 Cancer. Introduction
Introduction 1 1.1 Cancer 1 Introduction Cancer is the most precarious disease characterized by uncontrolled proliferation of cells without any physiological demands of the organism. Cancer may be defined
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationThe AML subtypes are based on how mature (developed) the cancer cells are at the time of diagnosis and how different they are from normal cells.
What is Acute Myeloid Leukemia (AML)? Acute myeloid leukemia (AML) is a cancer of cells in the blood, bone marrow and lymph nodes. AML is also called acute nonlymphocytic leukemia, acute myeloblastic leukemia,
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationCase Report. Introduction. Mastocytosis associated with CML Hematopathology - March K. David Li 1,*, Xinjie Xu 1, and Anna P.
Mastocytosis associated with CML Hematopathology - March 2016 Case Report Systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease (SM-AHNMD) involving chronic myelogenous
More informationWelcome and Introductions
Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationWe updated the design of this site on December 18, Previous Study Return to List Next Study
We updated the design of this site on December 18, 2017. Learn more. Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: AC220-A-U302 Previous Study Return to List Next
More informationSingle Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia
Single Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091534 Age 36 Years Gender Female 1/9/2017 120000AM 1/9/2017 105316AM 2/9/2017 104147AM Ref By Final LEUKEMIA GENETIC ROFILE ANY SIX MARKERS, CR QUALITATIVE AML ETO
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 24 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Aliyah Rahemtullah 1, Martin K Selig 1, Paola Dal Cin 2 and Robert P Hasserjian 1 Departments of Pathology,
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationComplete response of myeloid sarcoma with cardiac involvement to radiotherapy
Brief Report Complete response of myeloid sarcoma with cardiac involvement to radiotherapy Wen-Chi Yang 1, Ming Yao 2, Yu-Hsuan Chen 1,3, Sung-Hsin Kuo 1,3,4 1 Division of Radiation Oncology, Department
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationProtocol. Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia
Hematopoietic Stem-Cell Transplantation for Acute Myeloid (80126) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/15 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 05/10, 05/11,
More informationBCR-ABL1 positive Myeloid Sarcoma Nicola Austin
BCR-ABL1 positive Myeloid Sarcoma Nicola Austin Cytocell UK & Ireland User Group Meeting Jesus College, Cambridge 4 th - 5 th April 2017 Myeloid Sarcoma WHO Classification Tumours of Haematopoietic and
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationAcute myeloid leukemia (AML) is a
R E S E A R C H P A P E R Cytogenetic Profiles of 472 Indian Children with Acute Myeloid Leukemia ANUDISHI TYAGI 1, RAJA PRAMANIK 1, SHILPI CHAUDHARY 1, ANITA CHOPRA 2 AND SAMEER BAKHSHI 1 From Departments
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More informationJ Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION
VOLUME 34 NUMBER 29 OCTOBER 10, 2016 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationHow I treat extramedullary acute myeloid leukemia
How I treat How I treat extramedullary acute myeloid leukemia Richard L. Bakst, 1 Martin S. Tallman, 2 Dan Douer, 2 and Joachim Yahalom 1 1 Department of Radiation Oncology and 2 Leukemia Service, Department
More informationTest Name Results Units Bio. Ref. Interval. Positive
LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23
More informationHAEMATOLOGICAL MALIGNANCY
HAEMATOLOGICAL MALIGNANCY Reference Compulsory reading Haematology at Glance 2 nd ed. Atul Mehta & Victor Hoffbrand Chapters: 20 to 31 Pages: 46 to 69 Pathogenesis of Haematological Malignancy Figure (a)
More informationGroup of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and
Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type
More informationAcute Leukemia. Sebastian Giebel. Geneva 03/04/
Acute Leukemia (including ALL) Sebastian Giebel Geneva 03/04/2012 www.ebmt.org Acute leukemias: EBMT survey 2 AML: EBMT survey Gratwohl A, et al. Bone Marrow Transplant 2009 3 Acute leukemias: INCIDENCE
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationA review of central nervous system leukaemia in paediatric acute myeloid leukaemia
EDITORIAL A review of central nervous system leukaemia in paediatric acute myeloid leukaemia Donna L. Johnston Division of Hematology/Oncology, Children s Hospital of Eastern Ontario, Ottawa, Ontario,
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationNUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia
Case 0094 NUP214-ABL1 Fusion: A Novel Discovery in Acute Myelomonocytic Leukemia Jessica Snider, MD Medical University of South Carolina Case Report - 64 year old Caucasian Male Past Medical History Osteoarthritis
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationChildhood Leukemia Early Detection, Diagnosis, and Types
Childhood Leukemia Early Detection, Diagnosis, and Types Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationPacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018 Outline Case study Introduction of Current management of infantile
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationCurrent Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review
EXPERT OPINION Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review Chi-Kong Li Department of Pediatrics, Prince of Wales Hospital, The Chinese University
More informationUtility of FDG PET/CT in the Assessment of Myeloid Sarcoma
Nuclear Medicine and Molecular Imaging Pictorial Essay Nuclear Medicine and Molecular Imaging Pictorial Essay Elaine Yuen Phin Lee 1 Marina-Portia nthony 1 nskar Yu-Hung Leung 2 Florence Loong 3 Pek-Lan
More informationCase Report Myeloid Sarcoma Presenting with Leukemoid Reaction in a Child Treated for Acute Lymphoblastic Leukemia
Case Reports in Hematology, Article ID 757625, 5 pages http://dx.doi.org/10.1155/2014/757625 Case Report Myeloid Sarcoma Presenting with Leukemoid Reaction in a Child Treated for Acute Lymphoblastic Leukemia
More informationAcute Myeloid Leukemia Early Detection, Diagnosis, and Types
Acute Myeloid Leukemia Early Detection, Diagnosis, and Types Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationCharacteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies
Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies Sabine Kayser, * Julia Krzykalla, Michelle A. Elliott, Kelly Norsworthy, Patrick Gonzales,
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationImpact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases
DOI:10.22034/APJCP.2018.19.2.421 RESEARCH ARTICLE Editorial Process: Submission:08/01/2017 Acceptance:12/09/2017 Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete
More informationMaterials and Methods
Acute Myeloid Leukemia with CD56 Expression HIGH INCIDENCE OF CD56 EXPRESSION AND RELAPSE RATE IN ACUTE MYELOID LEUKEMIA PATIENTS WITH t(8;21) IN TAIWAN Chi-Huang Hsiao, 1,3 Jih-Luh Tang, 1 Ming Yao, 1
More informationCase #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...
Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR
More informationUnusual Presentation of Bladder Myeloid Sarcoma Causing Acute Renal Failure: Case Report and Review of the Literature
H & 0 C l i n i c a l C a s e S t u d i e s Unusual Presentation of Bladder Myeloid Sarcoma Causing Acute Renal Failure: Case Report and Review of the Literature Sonia John, MD 1 Hussein Ali Ahmad, MD
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationDOWNLOAD OR READ : TREATMENT OF ACUTE LEUKEMIAS NEW DIRECTIONS FOR CLINICAL RESEARCH REPRINT PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF ACUTE LEUKEMIAS NEW DIRECTIONS FOR CLINICAL RESEARCH REPRINT PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of acute leukemias new directions for clinical research reprint
More informationDaunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Find Studies About Studies Submit Studies Resources About Site Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia The safety and scientific validity
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationExtramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report
Cell Biochem Biophys (2014) 70:409 414 DOI 10.1007/s12013-014-9926-3 ORIGINAL PAPER Extramedullary Relapse of the AML Transformed from MDS Following Auto-HSCT: A Case Report Jin Wang Yu Liu Xu Zhou Zheng
More informationTransition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology
Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent
More informationCorrelation of Sex and Remission of Acute Lymphoblastic Leukemia-L1 (ALL-L1) in Children
International Journal of Clinical and Experimental Medical Sciences 2015; 1(2): 11-15 Published online July 6, 2015 (http://www.sciencepublishinggroup.com/j/ijcems) doi: 10.11648/j.ijcems.20150102.12 Correlation
More informationOriginal Article. Clinical features and outcome of acute myeloid leukemia, a single institution experience in Saudi Arabia INTRODUCTION
Original Article Clinical features and outcome of acute myeloid leukemia, a single institution experience in Saudi Arabia Ahmed Al Faleh 4, Abdullah Al-Quozi 2,3,4, Ahmed Alaskar 1,3,4, Mohsen Al Zahrani
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Solid Tumors of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_solid_tumors_childhood
More informationNew treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke
University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version
More informationCharles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162
Charles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162 Definition Pathophysiology Clinical signs and symptoms Biology and Diagnosis Different types of AL Prognosis and Treatment Malignant
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationLong-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationIsolated Pancreatic Myeloid Sarcoma Associated with
doi: 10.2169/internalmedicine.8912-17 Intern Med 57: 563-568, 2018 http://internmed.jp CASE REPORT Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/runx1-runx1t1 Rearrangement Kenji Tokunaga
More informationKeywords: Acute Myeloid Leukemia, FLT3-ITD Mutation, FAB Subgroups, Cytogenetic Risk Groups
Original Articleeee fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007-2008 Emami AH, 1 Shekarriz
More informationLeukemia and Myelodysplastic Syndromes
Leukemia and Myelodysplastic Syndromes Lenise Taylor, RN, MN, AOCNS Heme Malignancies/BMT CNS Seattle Cancer Care Alliance/UWMC Lymphoid 1 Myeloid 2 Presenting Signs and Symptoms Diagnostic Evaluation
More informationAn Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse
745 An Unusual Presentation of Chronic Myelogenous Leukemia: A Review of Isolated Central Nervous System Relapse Scott M. Lindhorst, MD a,b ; Richard D. Lopez, MD a ; and Ronald D. Sanders, MD c Abstract
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationAcute leukemia. Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation
Acute leukemia Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation Helocyte- Advisory board Acute myeloid leukemia (AML) Heterogeneous clonal malignancy
More informationMedical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in
More informationWHAT ARE PAEDIATRIC CANCERS
WHAT ARE PAEDIATRIC CANCERS INTRODUCTION Childhood cancers are RARE 0.5% of all cancers in the West Overall risk that a child will develop cancer during first 15 years of life is 1 in 450 and 1 in 600
More information